A Study of RO4989991 in Patients With Allergic Rhinitis
| Status: | Completed |
|---|---|
| Conditions: | Allergy, Asthma |
| Therapuetic Areas: | Otolaryngology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 8/3/2016 |
| Start Date: | July 2010 |
| End Date: | February 2011 |
A Multi-center, Randomized, Observer-blind, Placebo-controlled Safety and Tolerability Study of Repeated Administration of Two Dose Levels of RO4989991 Administered Subcutaneously to Patients With Allergic Rhinitis
This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the
safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic
rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.
safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic
rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.
Inclusion Criteria:
- Adult patients, 18-65 years of age, inclusively
- A history of allergic rhinitis diagnosed by a physician, but otherwise healthy
- A positive skin prick test to at least one standardized allergen at screening
- A body mass index (BMI) between 18 and 32 kg/m2, inclusively
Exclusion Criteria:
- History or presence of any respiratory disease or condition other than allergic
rhinitis
- Use of prescription medication or herbal remedies within 14 days of dosing the study
drug
- Use of over-the-counter (OTC) medications within 7 days of dosing the study drug
- Acute infection (including viral infections) 6 weeks (8 weeks for respiratory
infections) preceding dosing or any ongoing chronic infection
- Positive test for human immunodeficiency virus (HIV) or hepatitis B or C
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials